99 related articles for article (PubMed ID: 22209883)
1. Lobby groups call for closure of "revolving door" between drug regulators and industry.
Hawkes N
BMJ; 2011 Dec; 343():d8335. PubMed ID: 22209883
[No Abstract] [Full Text] [Related]
2. Professional ethics--business ethics.
Crombie HD
Conn Med; 2011 May; 75(5):303. PubMed ID: 21678845
[No Abstract] [Full Text] [Related]
3. Ethics Advisory Group of the International Union Against Tuberculosis and Lung Disease: policy and operational guidelines.
Ethics Advisory Group
Int J Tuberc Lung Dis; 2007 Dec; 11(12):1272-81. PubMed ID: 18034947
[No Abstract] [Full Text] [Related]
4. Dealing with drug dependency: a commentary on ILAE's partnership with the pharmaceutical industry.
Avanzini G; Engel J
Epilepsia; 2007 Oct; 48(10):1821-4. PubMed ID: 17683507
[No Abstract] [Full Text] [Related]
5. Core ethical values for European bioindustries.
Fears R; Tambuyzer E
Nat Biotechnol; 1999 Feb; 17(2):114-5. PubMed ID: 10052333
[No Abstract] [Full Text] [Related]
6. EuropaBio's ethics committee and Advisory Group on Ethics(AGE): an overview.
Tambuyzer E; Moll N; Muys P
J Biolaw Bus; 2002; 5(2):56-8. PubMed ID: 12739547
[No Abstract] [Full Text] [Related]
7. What's wrong with home care? An administrative ethics perspective.
Salvatore T; Baxter T
J Ethics Law Aging; 1998; 4(2):69-78. PubMed ID: 11657721
[No Abstract] [Full Text] [Related]
8. [Increased commercial financing of national Medical Product Agencies within the EU].
Ramel B
Lakartidningen; 2003 Jan; 100(5):338-9. PubMed ID: 12607381
[No Abstract] [Full Text] [Related]
9. Responses to the Gagnon report and REBs.
Gagnon D;
NCBHR Commun; 1993; 4(2):3-5. PubMed ID: 11652886
[No Abstract] [Full Text] [Related]
10. American IRBs and Dutch research ethics committees: how they compare.
Bergkamp L
IRB; 1988; 10(5):1-6. PubMed ID: 11650072
[No Abstract] [Full Text] [Related]
11. [The Medical Product Agency's work and economics--a comment].
Ahlqvist Rastad J; Salmonson T
Lakartidningen; 2003 Jan; 100(5):345. PubMed ID: 12607382
[No Abstract] [Full Text] [Related]
12. European Commission takes on Big Pharma.
den Exter A
Lancet; 2009 Aug; 374(9690):599-600. PubMed ID: 19699998
[No Abstract] [Full Text] [Related]
13. Substandard and counterfeit medicines.
Rassool GH
J Adv Nurs; 2004 May; 46(3):338-9. PubMed ID: 15119344
[No Abstract] [Full Text] [Related]
14. The Deschamps Report: controls for clinical research in Quebec.
Miller J
J Int Bioethique; 1997; 8(1-2):79-85. PubMed ID: 11655382
[No Abstract] [Full Text] [Related]
15. Ethical issues arising from commercial sponsorship and from relationships with the pharmaceutical industry--report and recommendations of the Ethics Subcommittee of the International Headache Society.
Steiner TJ
Cephalalgia; 2008 Sep; 28 Suppl 3():1-25. PubMed ID: 18666973
[No Abstract] [Full Text] [Related]
16. Anticipating a Vioxx defense strategy: will corporate honesty be enough?
Willis KD
Tort Trial Insur Pract Law J; 2006; 41(4):1163-78. PubMed ID: 17091567
[No Abstract] [Full Text] [Related]
17. Establishment and work of ethics committees in central and eastern European countries.
Glasa J
Med Etika Bioet; 2002; 9(1-2):9-12. PubMed ID: 16276662
[TBL] [Abstract][Full Text] [Related]
18. An integrated ethics program for managed care organizations.
Potter RL
Trends Health Care Law Ethics; 1995; 10(1-2):87-90. PubMed ID: 7655243
[No Abstract] [Full Text] [Related]
19. An ethical argument in support of interactions between developing world countries and pharmaceutical/biotechnology companies involved in oncology drug development.
Markman M
Cancer; 2008 May; 112(9):1871-3. PubMed ID: 18318430
[No Abstract] [Full Text] [Related]
20. IRBs and pharmaceutical company funding of research.
Jellinek MS; Levine RJ
IRB; 1982 Oct; 4(8):9-10. PubMed ID: 11651693
[No Abstract] [Full Text] [Related]
[Next] [New Search]
